The Danish pharma giant is accelerating its assault on the obesity market from two distinct angles, pairing a blockbuster oral rollout with a long-term bet on implantable drug delivery. The strategy is already winning over analysts, even as technical indicators flash a note of caution.<\/p>\n
Novo Nordisk\u2019s oral Wegovy tablet has gained rapid traction in the US since its launch, capturing roughly 65% of all new prescriptions in the first quarter. That momentum helped the drug generate around $353.6 million in that period alone, comfortably beating consensus estimates. The momentum is now being exported: Wegovy\u2019s pill form became available in the UK on a private-payer basis this week, with a starter pack priced at \u00a369 and a monthly top dose running about \u00a3189. The National Health Service has yet to decide on reimbursement, but the company is banking on strong private demand.<\/p>\n
Clinical data support the push: patients using the tablet shed up to 17% of their body weight over roughly a year. Meanwhile, UK regulators have approved semaglutide \u2013 Wegovy\u2019s active ingredient \u2013 for an additional indication, advanced liver fibrosis, opening a fresh therapeutic front.<\/p>\n
On the pipeline side, Novo Nordisk is looking beyond daily pills. The company inked a non-exclusive agreement with Vivani Medical to evaluate NPM-139, a miniature semaglutide implant designed to deliver sustained drug release over an extended period. The partners plan to begin a Phase 1 study by mid-2026, using the existing Wegovy injection as a comparator. Financial terms of the collaboration were not disclosed.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n Analysts are taking notice. Danske Bank raised its price target on Novo Nordisk to 365 Danish kroner and reiterated a buy rating, citing strong US prescription data and the UK launch. The bank also lifted its revenue forecasts for the oral formulation.<\/p>\n Not all news was rosy. In Sweden, the TLV reimbursement authority rejected a subsidy application for an obesity drug in children, citing a pending appeal on an earlier request. Novo Nordisk Sweden expressed disappointment, though the decision is unlikely to move the needle in a market dominated by US and UK dynamics.<\/p>\n A bigger challenge looms in America. Starting January 2027, Novo Nordisk plans to cut Wegovy\u2019s US list price by roughly 50% and Ozempic\u2019s by about 35%. While the discounts will squeeze revenue per unit, they are aimed at widening access and boosting prescription volumes.<\/p>\n